- Details
- Philip Koo interviews Michael Kipper about the peer-to-peer PYLARIFY reader assistance program. Aimed at educating healthcare providers in accurately reading and interpreting PYLARIFY scans, the program seeks to enhance patient care and harmonize reporting across institutions. Dr. Kipper emphasizes that this initiative is not meant for over-reading studies but to extend understanding of PYLARIFY r...
|
- Details
- Philip Koo, Oliver Sartor, and Neal Shore discuss the revolutionary impact of PSMA PET in the detection and management of prostate cancer. The experts explain the approved indications of PSMA PET agents PSMA 11 and PYLARIFY, emphasizing their transformative role in managing high-risk and intermediate-risk prostate cancer patients. Drs. Shore and Sartor detail how these imaging technologies inform...
|
- Details
- Alicia Morgans has a conversation with Oliver Sartor regarding updates to the NCCN guidelines concerning patient selection for Lutetium treatment using PSMA PET scans. According to Dr. Sartor, the VISION trial based its approval of PSMA-617 Lutetium-177 on PSMA 11 gallium 68 in patient selection, but other PET scans are equally effective. The choice between PSMA-11 gallium-68 and DCFPYL F18 scans...
|
- Details
- Alicia Morgans and Tanya Dorff, discuss the updates to the NCCN guidelines since the approval of PSMA PET CT molecular imaging agents. They discuss new guidance based on the FDA-approved indications in the labels for the use of molecular imaging agents for detecting prostate cancer when PSA levels are still relatively low and when PSA levels are rising. Biographies: Tanya B. Dorff, MD., is an asso...
|
- Details
- In this Society of Nuclear Medicine and Molecular Imaging (SNMMI), Satellite Symposium entitled PSMA-Targeted PET Imaging and Interpretation: What Urologists Need to Know Michael Gorin, MD presents on PSMA-targeted PET Imaging of Prostate Cancer - A Primer for Urologists. Dr. Gorin starts with reviewing conventional imaging modalities for prostate cancer which have proved insufficient for detectin...
|
- Details
- Michael Morris, MD joins Charles Ryan, MD in a discussion on the United States (US) FDA Approval of PYLARIFY®, an F 18-labeled prostate-specific membrane antigen (PSMA) targeted positron emission tomography (PET) imaging agent. The F 18 tracer went through two qualifying clinical trials the CONDOR trial and then OSPREY trial. This is the first time a national commercial approval will render PSMA i...
|
- Details
- In this Society of Nuclear Medicine and Molecular Imaging (SNMMI) Satellite Symposium entitled PSMA-Targeted PET Imaging and Interpretation: What Urologists Need to Know Steven Rowe, MD presents on PSMA-Targeted PET Imaging: Metastatic Disease, Response Assessment, Future Directions, and Read Paradigms. In his talk, he focuses on PSMA PET imaging in the context of metastatic disease, both small vo...
|
- Details
- Following presentations from Micheal Gorin and Steven Rowe during this Society of Nuclear Medicine and Molecular Imaging (SNMMI) Satellite Symposium entitled PSMA-Targeted PET Imaging and Interpretation: What Urologists Need to Know presented in conjunction with the American Urological Association Annual Meeting, the pair engage in a question and answer session. Drs. Gorin and Rowe comment on thei...
|
- Details
- The CONDOR trial was one of two studies that supported the United States Federal Drug Administration (FDA) submission and subsequent approval of DCFPyL, an 18F radiolabeled PSMA directed PET tracer. The CONDOR trial focused specifically on the rising, the biochemically relapsed patient population, those who had surgery or radiation as their definitive primary therapy, biochemically relapsed, and t...
|
- Details
- In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen discuss The Journal of Urology publication on the Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate-Specific Membrane Antigen PET/CT with 18F-DCFPyL in Prostate Cancer Patients (OSPREY). Prostate cancer staging is critical in multiple steps in the disease continuum, from the initial diagnosis to the...
|
